A nurse practitioner, physician assistant or physician can open a peptide and longevity telemedicine clinic in about twelve weeks, but in 2026 the gating item is not the technology; it is what you may lawfully prescribe. Most of the peptides that drive search traffic sit outside both the FDA-approved list and the lists compounding pharmacies may draw from, so the durable model is a longevity practice built on approved and lawfully compounded therapies, with peptides added only where a licensed pharmacy can lawfully dispense them for a specific patient. This is a 2026 planning summary, not legal or medical advice; confirm every point with your state boards, your pharmacy and counsel, because this area changes month to month.
Why a longevity practice works as cash-pay telemedicine
Demand is broad: adults in their 30s to 60s who want more than a ten-minute visit, have heard about GLP-1 medications and testosterone from friends, and want a clinician who looks at the whole picture. Insurance covers little of it, so they expect to pay cash, and the work fits video care: intake, labs drawn near home, a video results review, medications shipped to the door and a repeating follow-up cadence. A longevity patient is typically managed monthly or quarterly for a year or more, which makes a small panel viable for a solo clinician. One caution: part of the demand is driven by influencer content about peptides you may not be able to prescribe; treat that interest as a lead source for an honest conversation, not a menu.
What a compliant longevity clinic actually treats
The clinics that survive scrutiny build on four pillars, with peptides as a narrow add-on rather than the headline.
- Hormone optimization. Testosterone for men with documented hypogonadism, menopause hormone therapy, thyroid management where indicated: FDA-approved therapies with clear monitoring standards.
- Metabolic health and weight. FDA-approved GLP-1 and dual-agonist medications prescribed on-label, with nutrition, resistance training and protein targets in the plan.
- Cardiometabolic risk. Lipids including ApoB and lipoprotein(a), insulin resistance, blood pressure and inflammatory markers, treated with approved medications and referred out beyond your scope.
- Lifestyle protocols. Sleep, training, nutrition and stress coaching with measurable targets; this is what justifies a membership fee between medication visits.
Peptides fit in only where a lawful product exists. Tesamorelin is FDA-approved for a narrow indication (excess abdominal fat in adults with HIV-associated lipodystrophy); any other use is off-label judgment that cannot be advertised as approved. Sermorelin was once approved, later withdrawn for commercial rather than safety reasons as commonly reported, and has historically been compounded; its current eligibility is reported inconsistently, so get the pharmacy’s written basis first. In a compliant clinic, peptide therapy means approved peptide drugs (the GLP-1s among them) first.
Labs, biomarker panels and monitoring
A typical baseline panel includes CBC, comprehensive metabolic panel, lipid panel with ApoB, lipoprotein(a) once, HbA1c and fasting insulin, hs-CRP, TSH and free T4, total and free testosterone with SHBG, estradiol, LH and FSH, prolactin, PSA for men, vitamin D, ferritin and B12, plus IGF-1 if growth-hormone-axis therapy is considered. Follow-up labs typically land six to eight weeks after a medication start, then quarterly in year one, then twice a year. Testosterone needs hematocrit, PSA and estradiol monitoring; GLP-1 therapy needs screening for medullary thyroid history, pancreatitis and gallbladder disease, and tracking of weight, lean mass and GI tolerance. Expect to hold hormone and metabolic CE, any credential you market, and documented competence in everything you prescribe.
Informed consent
Consent is layered: a telemedicine consent that meets your state’s rules; an off-label disclosure whenever the use differs from the label; a compounded-drug disclosure stating that the product is not FDA-approved or evaluated for safety or effectiveness and naming the pharmacy; the material risks; the monitoring the patient agrees to; and the cash price. Boards read consent forms first.
The 2026 peptide compliance picture
Every substance you might prescribe sits in one of three buckets: FDA-approved drugs, prescribable on-label and with judgment and disclosure off-label; bulk substances on the section 503A bulks list or under FDA enforcement discretion for it (Category 1), which a licensed 503A pharmacy may compound for a patient-specific prescription (outsourcing facilities work from a separate 503B list); and everything else, which cannot be lawfully compounded for human use however it is labeled.
Category 2 placements. In 2023 FDA placed a group of popular peptides in Category 2 of the 503A bulks list, the category for substances that raise significant safety risks. Reported placements included BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604 and others; confirm the current list on FDA’s 503A bulks page, because 2026 moved it. In April 2026 FDA gave notice that twelve of those peptides were coming off Category 2 after their nominations were withdrawn, and in July 2026 the Pharmacy Compounding Advisory Committee reviewed seven, recommending several (BPC-157, KPV, TB-500, MOTS-c, epitalon and semax are the reported names) and rejecting one. Removal from Category 2 is not placement in Category 1, and an advisory vote is a recommendation FDA is not bound to adopt. As of this writing no rulemaking has added these peptides to the bulks list, others (ipamorelin and CJC-1295 are reported among them) remain unresolved or in litigation, and further reviews run into early 2027.
What compounders can still dispense. A pharmacy may lawfully compound a peptide only if the substance is a component of an approved drug, has a USP or NF monograph, or sits on the bulks list or under enforcement discretion. Ask for the written basis for each product; if the answer is “research grade” or “we source from a supplier,” walk away. Growth hormone is separate: federal law restricts somatropin to FDA-approved uses, and prescribing it for anti-aging or athletic purposes is a federal offense.
GLP-1 medications. Tirzepatide came off FDA’s shortage list in late 2024 and semaglutide in early 2025, ending the shortage basis for compounding copies; FDA has stated it ended enforcement discretion, proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, and in March 2026 sent warning letters to roughly thirty telehealth companies over compounded GLP-1 marketing that implied sameness with approved drugs. The compliant default is approved products through a retail or specialty pharmacy, with patient-specific compounding reserved for a documented clinical need counsel will defend.
“Research use only” peptides. The label is a seller’s legal posture, not a quality standard, and gives a clinician no cover. FDA has sent warning letters to research-peptide sellers; in 2026 the Mississippi medical, nursing and pharmacy boards jointly barred licensees from prescribing, administering, dispensing or recommending research-grade peptides, Alabama and South Carolina issued similar notices, and Ohio’s pharmacy board treats research-labeled vials in a clinic as unlawful possession, as reported. Malpractice carriers exclude unapproved products. Do not stock, administer or recommend them.
Marketing claims. FDA treats disease claims for a compounded or unapproved product as misbranding; FTC requires competent and reliable evidence for health claims, including claims made by affiliates you pay. Avoid “anti-aging cure,” implied FDA approval, before-and-after imagery that promises results, and any claim that a drug works for an unapproved use. Disclose compounded status and paid relationships; keep substantiation files.
Controlled substances and telemedicine. Testosterone is Schedule III, so each prescriber needs a DEA registration in each state of practice, any state controlled-substance registration, and a PDMP workflow. Federal telemedicine flexibilities allowing controlled-substance prescribing without a prior in-person exam run through December 31, 2026, and DEA’s special-registration final rule was under federal review as of this writing; confirm the current position before taking a testosterone patient. Licensure follows the patient’s location, and NP and PA authority, corporate-practice and good-faith-exam rules vary by state. The national layer is in the telemedicine hormone clinic compliance guide.
See the full 12-week program →
Operations: EHR, labs, pharmacy, shipping and intake
EHR. Certified electronic prescribing of controlled substances, routing to multiple pharmacies, a patient portal, video inside the chart and subscription billing, configured for cash-pay telehealth.
Labs. A client account with a national laboratory so the clinic orders and the patient uses a nearby draw site, plus direct-to-consumer and mobile phlebotomy options where they fit; direct-access rules vary by state.
Pharmacy. Vet every partner by license: licensure in the patient’s state, nonresident licenses for shipping across state lines, 503A versus 503B status, accreditation, certificates of analysis, sterile capability for injectables, cold-chain shipping with tracking, and the written basis for every peptide on its catalog; keep a backup. Approved GLP-1s and testosterone route to retail or specialty pharmacies.
Intake. A screening questionnaire that disqualifies before anyone pays, identity and location verification, the consent bundle, scheduling, pre-visit labs and a results-review visit, with written decision rules.
Economics of a longevity membership model
Hedged ranges from how cash-pay longevity practices typically price, not projections; your state, scope and acquisition effort decide where you land.
| Item | Typical range |
|---|---|
| Initial consultation with results review | $250–$450 |
| Baseline biomarker panel (cash lab pricing, passed through or bundled) | $200–$600 |
| Monthly management or membership | $150–$400 for lifestyle and monitoring; $300–$600 with medication management; medications and labs usually separate |
| Typical patient lifetime | 9–18 months, longer on hormone therapy |
On a monthly-management model priced around $300, ten patients can mean roughly $3,000 a month in recurring revenue, twenty-five around $7,500 and fifty around $15,000, before medication margin and labs, with those counts typically reached over months. The how to start a telemedicine hormone clinic guide covers pricing and subscription design in more detail.
Patient acquisition for a peptide and longevity clinic
Search intent is strong and specific: peptide therapy, longevity doctors, hormone optimization and GLP-1 care, in a city or online. Win it with honest educational content on what is lawfully available in 2026 and why, which also screens out patients who only want a product you cannot prescribe. A Google Business Profile is available where you meet patients at a real address; virtual-only practices are generally not eligible, so plan on organic search, referral and email. Referral partners that fit are trainers, physical therapists, dietitians and non-prescribing functional-medicine practitioners. Marketing compliance is part of the funnel: no compounded-drug claims, no implied approval, disclaimers on every therapy page, and affiliate agreements that require disclosure.
The 12-week Clinic In A Box map for this specialty
Clinic In A Box™ is a private, 1-on-1, done-with-you 12-week build led by an operator-mentor who runs active telemedicine clinics in the US, Colombia and Australia.
- Weeks 1–4, Foundation. Niche and patient avatar; the formulary decision (approved therapies first, peptides only with a written pharmacy basis); ownership model and entity filed with counsel; licenses, DEA, NPI; collaborating physician where required; HIPAA framework and an EHR with EPCS; the consent bundle.
- Weeks 5–8, Operations. Intake and screening; lab account and panels priced; pharmacies vetted by license and product basis, with a backup; monitoring schedules and decision rules; membership tiers, medication pricing and payment processing live; marketing claims reviewed.
- Weeks 9–12, Launch. Educational content, referral partners, Google Business where eligible, soft launch and first patients; a regulatory watch list (bulks-list rulemaking, DEA rule, state board notices); revenue and retention tracking; a 90-day roadmap.
Nurse practitioners can start with the nurse practitioner practice startup program page; physicians should read the physician telemedicine practice launch program page. The investment is $10,000 for two hours a week of direct work plus messaging between sessions; the curriculum is on the Clinic In A Box™ program page.
Who this is for, and who it is not for
It is a fit if you are a licensed NP, PA or physician who wants to serve hormone, metabolic and longevity demand on your own terms, or already run a practice whose formulary, consents and pharmacy relationships need fixing, and will tell patients no when what they want is not lawfully available.
It is not a fit if you want to sell research-grade peptides, plan to market compounded copies of approved drugs as equivalents, expect a promised income figure, are not yet licensed or are under board action, or want someone else to run the clinic.
Frequently asked questions
Can I prescribe BPC-157 in my clinic in 2026?
Not on a basis most counsel would defend as of this writing. BPC-157 is not an approved drug; it was placed in 503A Category 2 in 2023, reported removed in April 2026 and recommended for the bulks list by an advisory committee in July 2026, but FDA has not completed rulemaking, and removal from Category 2 does not authorize compounding. Check FDA’s 503A bulks page and your pharmacy’s written basis first.
Can I still prescribe compounded semaglutide or tirzepatide?
The shortage basis ended in 2024 and 2025, FDA has stated it ended enforcement discretion and proposed removing these drugs from the 503B bulks list, and the March 2026 warning letters targeted telehealth marketing of compounded versions. Approved products through a retail or specialty pharmacy are the compliant default; patient-specific compounding for a documented clinical need is an argument to run past counsel first.
Do I need a physician to start a peptide and longevity clinic as a nurse practitioner?
It depends on your state. Full practice states generally do not require a collaborating physician; reduced and restricted states require a collaborative or delegation agreement for some or all of practice, including prescribing, and corporate-practice rules may decide who owns the clinical entity. Confirm with your board of nursing and counsel.
Is growth hormone legal to prescribe for longevity or anti-aging?
No. Federal law restricts distribution of human growth hormone to FDA-approved uses such as diagnosed adult growth hormone deficiency; prescribing it for anti-aging, body composition or athletic performance is a federal criminal matter. Growth-hormone-releasing peptides are a separate category; treat each on its own regulatory basis.
Request your free info session
The next step is a free 30-minute info session covering your credential, your states, your formulary, your timeline and whether this is the right vehicle. Either way you leave with a clearer picture. Call 844-734-2112 or use the form below.